NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis $142.70 -0.59 (-0.41%) Closing price 04:00 PM EasternExtended Trading$140.60 -2.10 (-1.47%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Neurocrine Biosciences Stock (NASDAQ:NBIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurocrine Biosciences alerts:Sign Up Key Stats Today's Range$140.90▼$143.8350-Day Range$135.13▼$158.3552-Week Range$122.14▼$186.12Volume1.03 million shsAverage Volume1.36 million shsMarket Capitalization$14.51 billionP/E Ratio19.79Dividend YieldN/APrice Target$201.14Consensus RatingModerate Buy Company Overview Neurocrine Biosciences, Inc. is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs. Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company also markets ONGENTYS (opicapone), an adjunctive treatment for Parkinson’s disease, and CREXONT, an extended-release carbidopa and levodopa treatment for Parkinson’s disease. Its development pipeline includes additional investigational therapies in neuroscience and related fields. Founded in 1992, Neurocrine has built its business through internal research and collaborations with other pharmaceutical companies. Its commercial activities are primarily concentrated in the United States, while certain products and development programs may reach international markets through licensing and collaboration arrangements. The company is led by Kyle Gano, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Neurocrine Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreNBIX MarketRank™: 4.858056777285 of 5 starsNeurocrine Biosciences scored higher than 97% of companies evaluated by MarketBeat, and ranked 5th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 19 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialNeurocrine Biosciences has a consensus price target of $201.14, representing about 41.0% upside from its current price of $142.70.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth20.21% Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 20.21% in the coming year, from $7.72 to $9.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 19.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 19.79, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 192.53.Price to Earnings Growth RatioNeurocrine Biosciences has a PEG Ratio of 0.63. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.04% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 17.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.39 News SentimentNeurocrine Biosciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Neurocrine Biosciences this week, compared to 7 articles on an average week.Search Interest11 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat Follows6 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $720,855.00 in company stock.Percentage Held by Insiders4.60% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Stock News HeadlinesNeurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s TrialOctober 23 at 11:14 AM | finance.yahoo.comNeurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromeOctober 22 at 4:05 PM | prnewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 23 at 1:00 AM | Base Camp Trading (Ad)Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-'567 In Adults With Alzheimer's DiseaseOctober 21 at 9:04 AM | marketscreener.comMNeurocrine Biosciences, Inc.: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseaseOctober 21 at 9:04 AM | finanznachrichten.deNeurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseaseOctober 20 at 8:30 AM | prnewswire.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed as "Buy" by Needham & Company LLCOctober 18, 2026 | americanbankingnews.comNeurocrine Biosciences Presents 2-Year Results from Cahtalyst Pediatric and Cahtalyst Adult Studies of CrinecerfontOctober 17, 2026 | marketscreener.comMSee More Headlines NBIX Stock Analysis - Frequently Asked Questions How have NBIX shares performed this year? Neurocrine Biosciences' stock was trading at $141.83 at the beginning of the year. Since then, NBIX stock has increased by 0.6% and is now trading at $142.70. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings data on Friday, July, 31st. The company reported $2.85 earnings per share for the quarter, beating the consensus estimate of $1.65 by $1.20. Neurocrine Biosciences's revenue was up 39.5% on a year-over-year basis. Read the conference call transcript. How will Neurocrine Biosciences' stock buyback program work? Neurocrine Biosciences' board approved a stock buyback plan on Friday, February 21st 2025, which permits the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could buy up to 4.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board of directors believes its stock is undervalued. Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' top institutional investors include Ninety One UK Ltd (0.43%), Assenagon Asset Management S.A. (0.14%), Congress Asset Management Co. (0.12%) and Robeco Institutional Asset Management B.V. (0.11%). Insiders that own company stock include Kevin Charles Gorman, Kyle Gano, Gary A Lyons, Darin Lippoldt, Matt Abernethy, Eric Benevich, William H Rastetter, Richard F Pops, Jude Onyia, Eiry Roberts, Julie Cooke, Ingrid Delaet, Stephen A Sherwin, David W Boyer and Shalini Sharp. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurocrine Biosciences investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Walt Disney (DIS), AbbVie (ABBV), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings7/31/2026Today10/23/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NBIX's financial health is in the Red zone, according to TradeSmith. NBIX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NBIX CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees2,000Year Founded1992Price Target and Rating Average Price Target for Neurocrine Biosciences$201.14 High Price Target$253.00 Low Price Target$150.00 Potential Upside/Downside+41.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$6.82 Trailing P/E Ratio19.79 Forward P/E Ratio18.48 P/E Growth0.63Net Income$478.60 million Net Margins20.91% Pretax Margin27.87% Return on Equity22.43% Return on Assets15.64% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.75 Sales & Book Value Annual Sales$2.86 billion Price / Sales5.07 Cash Flow$4.99 per share Price / Cash Flow28.59 Book Value$32.63 per share Price / Book4.37Miscellaneous Outstanding Shares101,650,000Free Float96,973,000Market Cap$14.51 billion OptionableOptionable Beta0.40 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:NBIX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
